Holen Sie sich die Stockscreener-App
2.05
2.00%
0.05
Handel nachbörslich:
2.03
-0.02
-0.98%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.00
Offen:
$2.02
24-Stunden-Volumen:
5.12M
Relative Volume:
2.27
Marktkapitalisierung:
$215.86M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.34M
KGV:
-1.5074
EPS:
-1.36
Netto-Cashflow:
$-36.91M
1W Leistung:
+7.37%
1M Leistung:
+10.27%
6M Leistung:
+78.95%
1J Leistung:
+63.20%
1-Tages-Spanne:
$1.88
$2.08
1-Wochen-Bereich:
$1.8501
$2.15
52-Wochen-Spanne:
$0.772
$2.2691
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Firmenname
Sellas Life Sciences Group Inc
Sektor
Branche
Telefon
(646) 200-5278
Adresse
7 TIMES SQUARE, NEW YORK, NY
Vergleichen Sie SLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
2.05 | 249.97M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-07-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-11-01 | Eingeleitet | Oppenheimer | Outperform |
| 2018-04-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-19 | Hochstufung | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Aktie (SLS) Neueste Nachrichten
Quantitative breakdown of SELLAS Life Sciences Group Inc. recent move2025 Volume Leaders & Low Risk High Win Rate Stock Picks - newser.com
How to build a custom watchlist for SELLAS Life Sciences Group Inc.2025 Support & Resistance & Weekly Momentum Picks - newser.com
Can SELLAS Life Sciences Group Inc. stock sustain revenue growthJuly 2025 Macro Moves & Low Risk High Win Rate Stock Picks - newser.com
SELLAS to present CDK9 inhibitor data for T-cell leukemia at ESMO - Investing.com India
Biotech Stocks Surge After Hours On Trial Updates, Data Momentum - Nasdaq
Smart tools for monitoring SELLAS Life Sciences Group Inc.’s price actionWeekly Profit Report & Safe Capital Growth Stock Tips - newser.com
What technical models suggest about SELLAS Life Sciences Group Inc.’s comebackQuarterly Growth Report & Stepwise Trade Signal Guides - newser.com
SELLAS Life Sciences Stock Rises On Strong Preclinical Data For Investigational Cancer Treatment - Stocktwits
SELLAS Life Sciences to Present In Vivo Preclinical Data - GlobeNewswire
What analyst consensus says on SELLAS Life Sciences Group Inc. stockChart Signals & Risk Managed Investment Signals - newser.com
Using R and stats models for SELLAS Life Sciences Group Inc. forecastingTrade Signal Summary & Capital Efficient Trading Techniques - newser.com
How SELLAS Life Sciences Group Inc. stock valuations compare to rivalsQuarterly Portfolio Summary & Weekly High Return Stock Opportunities - newser.com
How institutional ownership impacts SELLAS Life Sciences Group Inc. stockPortfolio Update Summary & Target Return Focused Stock Picks - newser.com
SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025 - GlobeNewswire
SELLAS Life Sciences Group, Inc. to Present in Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia AAt the European Society for Medical Oncology Congress 2025 - MarketScreener
What data driven models say about SELLAS Life Sciences Group Inc.’s futureMarket Trend Review & Weekly Momentum Stock Picks - newser.com
Using data models to predict SELLAS Life Sciences Group Inc. stock movementJuly 2025 Decliners & Precise Entry and Exit Recommendations - newser.com
How to integrate SELLAS Life Sciences Group Inc. into portfolio analysis toolsPortfolio Performance Report & High Return Trade Guides - newser.com
Published on: 2025-10-09 03:27:21 - newser.com
Published on: 2025-10-09 03:07:14 - newser.com
Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth? - Sahm
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Significant Decrease in Short Interest - Defense World
Multi factor analysis applied to SELLAS Life Sciences Group Inc.July 2025 Momentum & Stepwise Entry/Exit Trade Alerts - newser.com
Using Python tools to backtest SELLAS Life Sciences Group Inc. strategies2025 Dividend Review & Free Accurate Trade Setup Notifications - newser.com
Can SELLAS Life Sciences Group Inc. (RXK3) stock double in coming years2025 Short Interest & Stock Market Timing Techniques - newser.com
Published on: 2025-10-06 05:59:31 - newser.com
SELLAS Extends Times Square Sublease Agreement - TipRanks
Why SELLAS Life Sciences Group Inc. (RXK3) stock benefits from AI revolutionEarnings Risk Summary & Community Consensus Picks - newser.com
Published on: 2025-10-03 03:10:59 - newser.com
Chart based analysis of SELLAS Life Sciences Group Inc. trendsJuly 2025 Patterns & Weekly Top Gainers Trade List - newser.com
Is SELLAS Life Sciences Group Inc. stock bottoming out2025 Buyback Activity & Daily Profit Focused Screening - newser.com
Published on: 2025-10-02 22:11:46 - newser.com
Will SELLAS Life Sciences Group Inc. (RXK3) stock test record highs in 20252025 Volume Leaders & High Conviction Investment Ideas - newser.com
SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update - Sahm
SELLAS Life Sciences to host virtual R&D day on AML treatments - Investing.com Nigeria
How Product Roadmap Could Affect Music Broadcast Limiteds Future ValueResistance Zone Identification & Free Stock Education Platform for New Investors - earlytimes.in
SELLAS Life Sciences to host virtual R&D day on AML treatments By Investing.com - Investing.com South Africa
What drives SELLAS Life Sciences Group Inc RXK3 stock priceHigh Beta Stocks & Fast Growing Investment Plans - earlytimes.in
Finanzdaten der Sellas Life Sciences Group Inc-Aktie (SLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):